- Investing.com
Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. The company’s product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hypercholesterolemia (HeFH); VERVE-102 that is being evaluated in the Heart-2 trial, an open-label Phase 1b clinical trial in adult patients with HeFH, and/or premature coronary artery diseases; VERVE-201, which targets ANGPTL3 and permanently turn off the ANGPTL3 gene in the liver; and VERVE-301, a development candidate that uses a novel in vivo gene editing approach to permanently turn off the LPA gene in the liver to reduce blood Lp(a) levels. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; a license agreement to lipid technology with Novartis Pharma AG; Eli Lilly and Company; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is based in Boston, Massachusetts. As of July 25, 2025, Verve Therapeutics, Inc. operates as a subsidiary of Ridgeway Acquisition Corporation.
Gene Editing Pionee | Verve Therapeutics leads cardiovascular treatment innovation with promising PCSK9 program results, showcasing potential for long-lasting genetic solutions |
Trial Triumph | Phase 1b Heart-2 trial data reveals significant PCSK9 and LDL-C reductions, paving the way for advanced studies and potential market disruption |
Strategic Partnerships | Collaboration with Eli Lilly bolsters Verve's position, offering financial support and expertise to accelerate development and commercialization efforts |
Market Valuation | Analyst targets range from $15 to $39 per share, reflecting optimism amid challenges. Strong liquidity and revenue growth offset cash burn concerns |
Metrics to compare | VERV | Peers Peers - average of corresponding metrics from companies closely matching VERV: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVERVPeersSector |
---|---|---|---|---|
P/E Ratio | −5.5x | 0.0x | −0.5x | |
PEG Ratio | −0.21 | 0.00 | 0.00 | |
Price/Book | 2.1x | 0.0x | 2.6x | |
Price / LTM Sales | 16.7x | 0.0x | 3.3x | |
Upside (Analyst Target) | 19.0% | 0.0% | 42.4% | |
Fair Value Upside | Unlock | 0.0% | 7.2% | Unlock |